UN Joint Statement Advocating for Universal Sexual and Reproductive Health and Rights
In April, at the United Nations Headquarters in New York, governments reaffirmed their commitment to the Programme of Action from the 1994 International Conference on Population and Development (ICPD). The…
AbbVie Seeks FDA and EMA Approval for Upadacitinib (RINVOQ®) to Treat Giant Cell Arteritis
Today, AbbVie announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new indication for upadacitinib (RINVOQ®; 15…
Daiichi Sankyo Launches New Oncology Affiliate in Greece
Daiichi Sankyo (TSE: 4568) has inaugurated a new affiliate dedicated to its oncology business in Athens, Greece, underscoring its commitment to addressing the needs of cancer patients in Europe. Thomais…
NICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis Treatment in NHS England for Eligible Adolescents and Adults
Lebrikizumab has been approved for treating moderate-to-severe atopic dermatitis in adolescents (12 years and older) and adults who require systemic therapy. This treatment received approval from the European Commission and…
CytoTronics Advances Live Cell Monitoring and Introduces Pixel Octo for High-Throughput Cell Biology Discovery
This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates…
Precision Neuromodulation Reduces Brain Atrophy and Boosts Connectivity in Alzheimer’s Patients
Sinaptica, a clinical-stage company pioneering personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the publication of a study in Alzheimer’s Research & Therapy. The study utilized MRI…
Harrow Signs 340B Prime Vendor Contract with Apexus™ for IHEEZO® and Key Products
Harrow, a prominent North American eyecare pharmaceutical firm, announced today its agreement with Apexus to include IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% and other key products in the 340B Prime…
Xeris Biopharma Unveils New CEO Succession Strategy
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company focused on developing and commercializing innovative products, announced a CEO succession plan effective August 1, 2024. Paul R. Edick will retire…
Ligand to Acquire APEIRON Biologics AG in a $100 Million Deal
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has announced a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. APEIRON holds royalty rights to QARZIBA® (dinutuximab beta), a treatment…
Adicet Bio Secures FDA Fast Track Designation for ADI-270 in Advanced Metastatic Clear Cell Renal Cell Carcinoma
Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has…
Epsilogen Receives CTA Approval for Phase Ib Trial of MOv18 IgE in Platinum-Resistant Ovarian Cancer
Epsilogen Receives CTA Approval for Phase Ib Trial of MOv18 IgE in Platinum-Resistant Ovarian Cancer Epsilogen has announced that it has received Clinical Trial Authorization (CTA) approval for a Phase…
Commending Ten Years of the Severe Acute Respiratory Infections Network in the Americas
The Severe Acute Respiratory Infections Network (SARInet) is a regional collaboration comprising professionals from hospitals, laboratories, health organizations, and institutions across Member States of the Americas. SARInet, coordinated by the…